PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma
Abroad (travel likely)Not Yet RecruitingPHASE1, PHASE2
Conditions
Diffuse Midline Glioma · Diffuse Midline High-grade Glioma · Medulloblastoma · Ependymoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Washington University School of Medicine, St Louis, Missouri, United States
Contact: Study coordinator (Eric M Thompson, M.D.) · pedshemonctrialreferral@wustl.edu · 314-454-2810Contact: Principal Investigator (Eric M Thompson, M.D.)Mohamed Abdelbaiki, M.D. (Sub-investigator)Feng Gao, M.D., MPH (Sub-investigator)Joshua Shimony, M.D., Ph.D. (Sub-investigator)Duke University Medical Center, Durham, North Carolina, United States
Contact: Principal Investigator (Daniel Landi, M.D.)MD Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Gregory Friedman, M.D.)
Study leads
Eric M Thompson, M.D.
Principal Investigator
Washington University School of Medicine